Arcus Biosciences, Inc. RCUS
$19.10
-19.58%
at last close
Analyst Consensus
- Consensus Rating
- Buy (10 Buy · 3 Hold · 0 Sell)
- Average Price Target
- $39.00
- Implied Upside
- +104.2%
- Price Target Range
- $22.00 – $50.00
- Analysts (12 mo)
- 13
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-10-21 | CitigroupYigal Nochomovitz |
Maintains | Buy | $45 → $50 |
| 2026-10-21 | Truist SecuritiesSupawat Thongthip |
Maintains | Buy | $40 → $41 |
| 2026-10-21 | WedbushRobert Driscoll |
Maintains | Outperform | $43 → $49 |
| 2026-10-16 | William BlairAlethia Young |
Initiates coverage on | Outperform | — |
| 2026-10-14 | JP MorganPriyanka Grover |
Initiates coverage on | Overweight | $41 |
| 2026-09-30 | WedbushRobert Driscoll |
Reiterates | Outperform | $43 |
| 2026-09-16 | TD CowenTara Bancroft |
Initiates coverage on | Buy | — |
| 2026-09-08 | Truist SecuritiesSupawat Thongthip |
Reiterates | Buy | $35 → $40 |
| 2026-08-06 | Wells FargoEva Fortea Verdejo |
Maintains | Equal-weight | $23 → $26 |
| 2026-08-06 | WedbushRobert Driscoll |
Maintains | Outperform | $41 → $43 |
| 2026-07-20 | HC Wainwright & Co.Emily Bodnar |
Maintains | Buy | $32 → $45 |
| 2026-06-04 | LifeSci CapitalCharles Zhu |
Initiates coverage on | Outperform | $46 |
| 2026-05-18 | Truist SecuritiesSupawat Thongthip |
Assumes | Buy | $30 → $35 |
| 2026-05-11 | Morgan StanleyTerence Flynn |
Maintains | Equal-weight | $20 → $22 |
| 2026-05-07 | Goldman Sachs Richard Law |
Maintains | Buy | $30 → $34 |
| 2026-04-02 | WedbushRobert Driscoll |
Maintains | Outperform | $37 → $41 |
| 2026-03-05 | CitigroupYigal Nochomovitz |
Maintains | Buy | $44 → $45 |
| 2026-03-02 | Leerink PartnersGeoffrey Porges |
Maintains | Outperform | $36 → $49 |
| 2026-03-02 | HC Wainwright & Co.Emily Bodnar |
Reiterates | Buy | $32 |
| 2026-02-12 | Wells FargoEva Fortea Verdejo |
Downgrades | Overweight → Equal-weight | $30 → $23 |
| 2026-01-13 | Goldman Sachs Richard Law |
Upgrades | Neutral → Buy | $16 → $28 |
| 2026-01-08 | Morgan StanleyTerence Flynn |
Downgrades | Overweight → Equal-weight | $23 → $20 |
| 2025-12-12 | HC Wainwright & Co.Emily Bodnar |
Maintains | Buy | $28 → $32 |
| 2025-11-28 | B of A SecuritiesJason Zemansky |
Maintains | Neutral | $17 → $26 |
| 2025-10-30 | Goldman SachsSalveen Richter |
Maintains | Neutral | $14 → $16 |
| 2025-10-29 | CitigroupYigal Nochomovitz |
Maintains | Buy | $54 → $56 |
| 2025-10-29 | HC Wainwright & Co.Emily Bodnar |
Maintains | Buy | $24 → $28 |
| 2025-10-20 | Wells FargoEva Fortea Verdejo |
Maintains | Overweight | $25 → $29 |
| 2025-10-13 | CitigroupYigal Nochomovitz |
Maintains | Buy | $47 → $54 |
| 2025-10-07 | Truist SecuritiesAsthika Goonewardene |
Reiterates | Buy | $32 → $39 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $19.10
- Market Cap
- $3.02 billion
- 52-Week Range
- $11.68 – $31.73
- Average Volume
- 1.97 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.